Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2020

View Archived Issues

Bromodomain 2-selective BET inhibitors show antitumor effect in pediatric cancer models

Medicenna outlines phase III plans for MDNA-55 in recurrent glioblastoma

NIAID initiates phase I study of SAR-440894

Avalyn advances phase I/II study of AP-101 in IPF

Recce receives ethics approval to initiate phase I/II burn wound study of RECCE-327

CKD-508, second-generation CETP inhibitor with improved safety and efficacy

Medshine Discovery patents Ret inhibitors

Neutrophils are literal obstacle to stroke recovery

Albumin transports proteins across mucosa, into lymph nodes

Insilico Medicine discloses JAK inhibitors

Epizyme presents CREBBP and KAT3B inhibitors

FZD6 as novel biomarker of depression

Ventyx Biosciences discloses TYK2 ligands

WHO Solidarity interim results show repurposed antivirals for COVID-19 have little or no effect

Baylor College of Medicine identifies new antiviral compounds

TRPA1 channel as a new therapeutic target for chronic post-thoracotomy pain

New model created for CFTR gene nonsense mutation W1282X cystic fibrosis

Cellular "pantry" of sorts, lipid droplets double as home security system

Snai1 inhibition may ameliorate right ventricular failure due to pulmonary hypertension

Furin inhibitor BOS-318 seems effective for treating cystic fibrosis

PharmaMar reports data from APLICOV-PC trial with Aplidin in COVID-19

Agios withdraws MAA for Tibsovo for relapsed or refractory AML with IDH1 mutation

Orion's OB-002H for prevention of HIV completes first-in-human study

Aptose begins phase Ia/b study of CG-806 in AML

FDA clears Mereo to begin phase Ib/II basket study of etigilimab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 31, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026